@article{ae075e1cec7b4357b8dfbae725542ab7,
title = "Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy",
abstract = "A trial to evaluate the safety and immunogenicity of recombinant modified vaccinia Ankara (MVA) and fowlpox (FP) vectors expressing multiple HIV-1 proteins was conducted in twenty HIV-1 infected youth with suppressed viral replication on HAART. The MVA and FP-based multigene HIV-1 vaccines were safe and well tolerated. Increased frequencies of HIV-1 specific CD4+ proliferative responses and cytokine secreting cells were detected following immunization. Increased frequencies and breadth of HIV-1 specific CD8 T-cell responses were also detected. Plasma HIV-1-specific antibody levels and neutralizing activity were unchanged following vaccination. Poxvirus-based vaccines may merit further study in therapeutic vaccine protocols.",
keywords = "HIV-1, Therapeutic immunization, Vaccine",
author = "Greenough, {Thomas C.} and Cunningham, {Coleen K.} and Petronella Muresan and Margaret McManus and Deborah Persaud and Terry Fenton and Piers Barker and Aditya Gaur and Dennis Panicali and Sullivan, {John L.} and Katherine Luzuriaga",
note = "Funding Information: Source(s) of support: Protocol development and patient enrollment were funded by the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Child Health and Human Development through the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT; U01-AI-068632 and N01-HD-33345), the National Center for Research Resources (General Clinical Research Centers). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAID or the National Institutes of Health. Laboratory studies were supported by the IMPAACT network laboratories (U01 AI-069516), the University of Massachusetts Center for AIDS Research Clinical Investigation and Molecular Virology Cores (AI-042845), and by NIH grants HD-001489 and AI-032391 (KL). The investigational vaccines were provided by Therion Biologics Corporation. Conflict of interest: All authors have contributed significantly to the work, have approved the manuscript, and concur with its submission. The manuscript material has not been previously reported, nor is it under consideration for publication elsewhere. There are no conflicting financial interests.",
year = "2008",
month = dec,
day = "9",
doi = "10.1016/j.vaccine.2008.09.084",
language = "English (US)",
volume = "26",
pages = "6883--6893",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "52",
}